|Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.|
|Jump to Full Text|
|PMID: 20683448 Owner: NLM Status: MEDLINE|
|BACKGROUND: In this report we investigated the combination of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) pathway inhibition as a possible new therapeutic strategy for small cell lung cancer (SCLC).
METHODS: EGFR, p-AKT, p-ERK, p-mTOR and p-p70s6K protein expressions were studied by immunohistochemistry in 107 small cell lung carcinomas and correlated with clinicopathological parameters. Cells of SCLC were treated with erlotinib+/-RAD001 and analysed for cell viability, proliferation, autophagy, and pathway regulation.
RESULTS: Epidermal growth factor receptor, p-AKT, p-ERK, p-mTOR, and p-p70s6K were expressed in 37, 24, 13, 55 and 91% of the tumour specimens of all SCLC patients, respectively, and were not associated with disease-free or overall survival. The expression of EGFR was lower in neoadjuvant-treated patients (P=0.038); mTOR pathway activation was higher in the early stages of disease (P=0.048). Coexpression of EGFR/p-mTOR/p-p70s6K was observed in 28% of all patients . EGFR immunoreactivity was associated with p-ERK and p-mTOR expression (P=0.02 and P=0.0001); p-mTOR immunoreactivity was associated with p-p70s6K expression (P=0.001). Tumour cells comprised a functional EGFR, no activating mutations in exons 18-21, and resistance to RAD001 monotherapy. We found synergistic effects of erlotinib and RAD001 combination therapy on the molecular level, cell viability, proliferation and autophagy.
CONCLUSIONS: The combined inhibition of EGFR/mTOR pathways could be a promising approach to treat SCLC.
|K Schmid; Z Bago-Horvath; W Berger; A Haitel; D Cejka; J Werzowa; M Filipits; B Herberger; H Hayden; W Sieghart|
Related Documents :
|1322838 - Effects of bradykinin on cell volume and intracellular ph in nih 3t3 fibroblasts expres...
3047398 - Crystallization and preliminary crystallographic data of a truncated derivative from th...
3127778 - The transformation of primary and established mouse mammary epithelial cells by p21-ras...
3099298 - Loss of platelet-derived growth factor-stimulated phospholipase activity in nih-3t3 cel...
6985268 - Biochemical separation of a human b cell mitogenic factor.
18265318 - Overview of schizosaccharomyces pombe.
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-08-03|
|Title: British journal of cancer Volume: 103 ISSN: 1532-1827 ISO Abbreviation: Br. J. Cancer Publication Date: 2010 Aug|
|Created Date: 2010-08-24 Completed Date: 2010-09-10 Revised Date: 2013-06-03|
Medline Journal Info:
|Nlm Unique ID: 0370635 Medline TA: Br J Cancer Country: England|
|Languages: eng Pagination: 622-8 Citation Subset: IM|
|Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.|
|APA/MLA Format Download EndNote Download BibTex|
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
Lung Neoplasms / drug therapy
Protein-Serine-Threonine Kinases / antagonists & inhibitors*
Quinazolines / administration & dosage*
Receptor, Epidermal Growth Factor / antagonists & inhibitors*
Signal Transduction / drug effects
Sirolimus / administration & dosage, analogs & derivatives*
Small Cell Lung Carcinoma / drug therapy*, metabolism
TOR Serine-Threonine Kinases
|0/Intracellular Signaling Peptides and Proteins; 0/Quinazolines; 0/Xenopus Proteins; 0/tumorhead protein, Xenopus; 159351-69-6/everolimus; 53123-88-9/Sirolimus; EC 220.127.116.11/MTOR protein, human; EC 18.104.22.168/TOR Serine-Threonine Kinases; EC 22.214.171.124/Receptor, Epidermal Growth Factor; EC 126.96.36.199/Protein-Serine-Threonine Kinases; J4T82NDH7E/erlotinib|
Journal ID (nlm-ta): Br J Cancer
Publisher: Nature Publishing Group
Copyright © 2010 Cancer Research UK
Revision Received Day: 13 Month: 05 Year: 2010
Accepted Day: 07 Month: 06 Year: 2010
Print publication date: Day: 24 Month: 08 Year: 2010
Electronic publication date: Day: 03 Month: 08 Year: 2010
Volume: 103 Issue: 5
First Page: 622 Last Page: 628
Publisher Item Identifier: 6605761
PubMed Id: 20683448
|Dual inhibition of EGFR and mTOR pathways in small cell lung cancer Alternate Title:EGFR/mTOR inhibition in SCLC|
1Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
2Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria
3Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria
The options for successful treatment of small cell lung cancer (SCLC) are still very poor. From the time of diagnosis, the median survival rates for SCLCs are 15–20 (limited disease SCLC) and 8–13 months (extended disease SCLC), respectively (Puglisi et al, 2010); therefore, new therapeutic strategies are urgently needed.
The epidermal growth factor receptor (EGFR) pathway is a well-known molecular target in several human tumours. Small molecules inhibiting EGFR such as erlotinib or gefitinib as well as anti-EGFR antibodies such as cetuximab were successfully tested in non-SCLC, head and neck, pancreatic and colon cancer (Ciardiello and Tortora, 2008).
Until now, the EGFR pathway has not been studied extensively in SCLC. There are little and controversial data about the presence of EGFR in SCLC tissue (Fischer et al, 2007). It was shown that treatment of SCLC cell lines with a monoclonal EGFR antibody reduced invasiveness of tumour cells in vitro (Damstrup et al, 1998). The tyrosin kinase inhibitor gefitinib, directed against the tyrosin kinase domain of the EGFR, showed single-agent activity against SCLC cells (Tanno et al, 2004), and reverted resistance to the chemotherapeutic topotecan in vitro (Nakamura et al, 2005), but failed to show clinical benefit in a recent phase II clinical trial in patients with SCLC (Moore et al, 2006). These data suggest that targeting a single pathway in SCLC may not be efficient enough for successful treatment of this deadly disease.
The mammalian target of rapamycin (mTOR) was intensively studied in a multitude of human tumour entities over the past couple of years. Different mitogens activate AKT, which controls mTOR activation by phosphorylation of TSC2, a component of tuberous sclerosis complexes 1 and 2. Activated mTOR phosphorylates 4EBP-1 and p-p70s6K, which leads to protein translation and tumour growth (Bjornsti and Houghton, 2004). AKT can also be activated by the EGFR (Ono and Kuwano, 2006), which represents a possible molecular link between the mTOR and the EGFR pathways.
The mTOR inhibitors CCI-779 and everolimus (RAD001) have already been approved for treatment of advanced renal cancer (Hudes et al, 2007; Motzer et al, 2008); together with other mTOR inhibitors, they are under clinical investigation for several other cancer indications. Although there is evidence that the mTOR pathway is active in SCLC cell lines (Fischer et al, 2007), mTOR pathway expression in SCLC tissue has not been investigated until now. The mTOR pathway may be involved in mechanisms of SCLC cells to escape cell death after treatment with DNA-damaging agents, as the mTOR inhibitor CCI-779 restored sensitivity of SCLC cells to cisplatin treatment (Belyanskaya et al, 2005; Wu et al, 2005). However, similar to gefitinib therapy, CCI-779 and RAD001 monotherapy achieved only little benefit for SCLC in recent phase II clinical trials (Pandya et al, 2005; Owonikoko et al, 2008).
Given the molecular connection of the EGFR and mTOR pathways, we hypothesised that dual inhibition of both pathways may be a suitable new strategy to treat SCLC. Thus, we investigated single and coexpression of both pathways in 107 SCLC tissue samples, their correlation with clinical–pathological parameters, and analysed efficacy of anti-EGFR therapy plus mTOR inhibition in SCLC cell lines.
The study comprised 107 patients (69 males and 38 females), median age 62 years (range 35–92 years), who underwent surgery for SCLC at the Department of Cardio-Thoracic Surgery, Medical University of Vienna, Austria. After surgery, tissue samples were fixed in 7.5% buffered formalin and embedded in paraffin for routine diagnostics. Neuroendocrine tumour differentiation was confirmed by immunohistochemical staining for neuroendocrine markers (chromogranin A and/or synaptophysin). Tumours were staged according to the International Union Against Cancer (UICC) 2004 issue of the TNM system and revealed pT1 in 36 (34%), pT2 in 55 (51%), pT3 in 4 (4%) and pT4 in 12 (11%) cases; lymph node metastases were present in 57 (53%) cases (pN1, pN2 and pN3 in 30, 21 and 2%, respectively). TNM stages corresponded to UICC stages IA, IB, IIA, IIB, IIIA and IIIB in 22 (21%), 23 (21%), 9 (8%), 18 (17%), 22 (21%) and 13 (12%) cases, respectively. The clinical follow-ups of the patients were retrospectively collected from the archives of the Department of Cardio-Thoracic Surgery, Medical University of Vienna, and respective hospitals performing their follow-ups; median-disease free and overall survival were 11.5 and 20.5 months, respectively (both range 0–179.9 months). In all, 20 (19%) patients received preoperative chemotherapy (cisplatin and etoposid). Adjuvant chemotherapy was known for 50 (47%) patients (cisplatin and etoposid, cisplatin and adriamycin or cyclophosphamid and oncovin; in some cases topotecan was given in second line). In all, 56 (52%) patient suffered tumour recurrence and 48 (45%) died of tumour progression during the observation period.
Immunohistochemistry was performed on 4 μm paraffin sections from one representative tissue block per patient stored at the archives of the Department of Pathology, Medical University of Vienna, using antibodies against EGFR (DAKO, Glostrup, Denmark) phospho-mTOR, phospho-p70s6K, phospho-AKT and phospho-ERK (all from Cell Signaling Technology, Danvers, MA, USA).
Epidermal growth factor receptor kit immunostaining was performed according to the manufacturer's instructions. Pretreatment was protease (Sigma, Steinheim, Germany) for p-AKT immunostaining, microwave (5 × 5 min, 900 W) for p-ERK immunostaining, and autoclave (20 min, 1 bar) for p-mTOR and p-p70s6K immunostaining. After blocking, samples were incubated with primary antibodies for 1 h at room temperature. Dilutions for anti-p-AKT, anti-p-ERK, anti-p-mTOR and anti-p-p70s6K were 1 : 25, 1 : 100, 1 : 100 and 1 : 400, respectively. After applying a biotinylated secondary antibody and tertiary reagent (Vector-Laboratories, Bulingam, CA, USA) the antibody binding was visualised by diaminobenzidine (Serva, Heidelberg, Germany) and H2O2. Colon carcinoma tissue served as positive control. Negative controls were treated with isotype IgG control antibodies. Immunoreactive tumour cells were counted in 10 high-power fields ( × 400) by KS and ZB independently. The scoring system integrated intensity and extent of immunostaining: the number of positive tumour cells was scored 0 (<10%), 1 (10–24%), 2 (25–49%), 3 (50–79%) and 4 (80–100%). Intensity of staining was scored 0 (negative), 1 (weak) or 2 (strong). The results of the extent and intensity of staining of tumour cells were summarised to assess the final score.
RAD001 (everolimus) was provided by The Novartis Institutes for BioMedical Research Basel, Oncology, Switzerland. Erlotinib was dissolved in DMSO and provided by Professor Thomas Grunt (Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria). Controls were treated with appropriate concentrations of DMSO.
Two SCLC cell lines were used: GLC-4, donated by Dr EG deVries, Groningen, The Netherlands (Zijlstra et al, 1987), and VL-68 (Berger et al, 2001). Cells were grown in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum and with 1% penicillin–streptomycin in a humidified atmosphere containing 5% CO2 (all from Gibco Life Technologies, Paisley, UK). Cell counts were determined using a CC-108 microcellcounter (Sysmex, Kobe, Japan). Cells growing in logarithmic phases of growth were used for all the studies described below.
Cells (2 × 105 cells per well) in the logarithmic phase of growth were plated in 0.5 ml complete medium in 48-well plates and allowed to attach overnight. The next day, RAD001, erlotinib or a combination of both were added at concentrations as indicated. The final concentration of DMSO never exceeded 0.5%. Cells were incubated for 72 h at 37 °C in a humidified atmosphere containing 5% CO2. Afterwards, medium was replaced by 100 μl Opti-MEM medium containing 1 mg ml–1 Thiazolyl Blue Tetrazolium Bromide (MTT; Sigma-Aldrich, Vienna, Austria) and incubated for 1 h at 37 °C. The cells were then lysed by adding 100 μl DMSO. Absorbance was recorded by a BioTek Synergy HT plate reader (BioTek Instruments, Winooski, VT, USA) at 570 nm. All experiments were run in triplicates.
Small cell lung cancer cells (0.4 × 106 per ml) were seeded in 25 cm2 tissue culture flasks and then incubated with RAD001, erlotinib or with a combination of both at concentrations as indicated. After 48 h, cells were harvested and propidium iodide staining was performed as reported by Sieghart et al (2007). Cell cycle analysis (including sub-G1 peak for apoptosis) was performed using a FACSCalibur flow cytometer (Becton Dickinson, Heidelberg, Germany) and cell cycle distribution was calculated using ModFit LT software (Verity Software House, Topsham, ME, USA). To further analyse apoptosis, we performed DAPI staining according to the study group of Dornetshuber et al (2007). Cell proliferation was measured using the 3H-thymidine incorporation assay (Dornetshuber et al, 2007) 24 h after treatment of SCLC cells with erlotinib, RAD001 or a combination of both at indicated concentrations.
The effect of the investigated compounds alone and in combination on autophagy was assessed in both SCLC models by quantification of acidic vesicular organelles. In brief, cells were seeded at 3 × 105 per well in six-well plates and treated with erlotinib, RAD001 and their combination at concentrations as indicated. After 48 h, cells were trypsinised, washed in PBS and stained with acridine orange (1 μg ml–1 in serum- and phenol red-free medium; Sigma-Aldrich) for 15 min at 37 °C. The cells were analysed through flow cytometry for green (510–530 nm) and red (>650 nm) fluorescence emission from 2 × 104 cells illuminated with blue (488 nm) excitation light, and were measured with FACSCalibur (Becton Dickinson) using CellQuest software. Cells positive for red fluorescence were scored positive for acidic vesicular organelles.
Genomic DNA used as template for sequencing EGFR exons 18–21 was extracted from the GLC-4 and VL-68 cell lines as described previously (Lynch et al, 2004). In brief, polymerase chain reaction (PCR) fragments were sequenced and analysed in both sense and anti-sense directions for the presence of heterozygous mutations. The primer sequences for exon 18 were 5′-CTGAGGTGACCCTTGTCTCTG-3′ (forward) and 5′-CCAAACACTCAGTGAAACAAAGAG-3′ (reverse); for exon 19 5′-TGCCAGTTAACGTCTTCCTT-3′ (forward) and 5′-CAGGGTCTAGAGCAGAGCAG-3′ (reverse); for exon 20 5′-CATTCATGCGTCTTCACCTG-3′ (forward) and 5′-TTATCTCCCCTCCCCGTATC-3′ (reverse); and for exon 21 5′-CTTCCCATGATGATCTGTCC-3′ (forward) and 5′-TTATCTCCCCTCCCCGTATC-3′ (reverse). Mutations were identified by visual analysis of the sequence chromatograms using SeqScape (Applied Biosystems, Foster City, CA, USA).
Cells (2 × 106 cells per well) in the logarithmic phase of growth were plated in 2 ml complete medium in six-well plates and allowed to attach overnight. Cells were treated with RAD001, erlotinib or with a combination of both at concentrations as indicated. They were then incubated for 72 h at 37 °C in a humidified atmosphere containing 5% CO2. After harvesting of the probes they were blotted according to standard procedures and incubated with monoclonal antibodies binding to EGFR (Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1 : 1000), p-AKT (1 : 5000), p-mTOR (1 : 3000), p-p70s6K (1 : 3000), p-ERK (all from Cell Signaling, 1 : 5000) or Actin (Sigma-Aldrich; 1 : 40 000), respectively. Reactive bands were detected by chemiluminescence (CSPD substrate; Tropix Inc., Bedford, MA, USA). Equal protein loading in each lane was documented by detecting Actin protein expression.
Association of different protein immunoreactivity among each other and with clinicopathological parameters was investigated using the χ2 test. Disease-free and overall survival was assessed using the Kaplan–Meier method. Cell culture data are presented as mean±s.d. Differences among treatment groups were calculated using one-way ANOVA, and Bonferroni's test was used for post hoc comparisons. For all tests, a two-tailed P-value of ⩽0.05 was considered significant.
Overall, EGFR, p-AKT and p-ERK expression was detected in 37, 24 and 13% of tumour specimens (Figure 1 and Table 1). P-AKT and p-ERK showed cytoplasmatic staining pattern, whereas EGFR was expressed cytoplasmatic and membranous. The expression of EGFR and p-ERK as well as of p-AKT and p-ERK was positively associated (P=0.02 and P=0.0001), whereas EGFR and p-AKT expression was not (P>0.05, Table 2). Patients receiving preoperative chemotherapy were less likely to present with EGFR-positive tumours than patients without preoperative chemotherapy (14 vs 40%, P=0.038), but no influence of preoperative chemotherapy on p-AKT or p-ERK tumour expression was found (both P>0.05, Table 2). The expression of EGFR, p-AKT and p-ERK was not associated with tumour stage, disease-free or overall survival on univariate analysis (all P>0.05, Table 2).
Phospho-mTOR and p-p70s6K immunoreactivities were detected in 55 and 91% tumour specimens of all SCLC patients (Figure 1 and Table 1). Phospho-mTOR was expressed in the cytoplasma and p-p70s6K was detected in the cytoplasma and/or in the nucleus. Mitoses showed a remarkable cytoplasmatic p-p70s6K staining pattern (see arrows in Figure 1B). There was a significant association of p-mTOR and p-p70s6K (P=0.001, Table 2). Higher tumour stages were associated with lower p-mTOR expression (P=0.048), but no association between p-mTOR expression and nodal stage was found (P>0.05, Table 2). Higher tumour and nodal stages presented with lower p-p70s6K tumour expression (P=0.02 and P=0.001, Table 2). Preoperative chemotherapy had no influence on p-mTOR and p-p70s6K tumour expression. Phospho-mTOR and p-p70s6K tumour expression had no influence on disease-free and overall survival in univariate analysis (P>0.05, Table 2).
In all, 28% of all patients showed coexpression of both pathways in terms of EGFR, p-mTOR and p-p70s6K positivity in SCLC tumour specimens. There was no significant difference in tumour or nodal stage distribution and administration of preoperative chemotherapy compared with patients without pathway coexpression (all P>0.05). A positive association between EGFR and p-mTOR expression (P=0.0001), but not between EGFR and p-p70s6K expression (P>0.05, Table 2), was found. There was no association between p-ERK, p-mTOR and p-p70s6K as well as p-AKT, p-mTOR and p-p70s6K tumour expression (all P>0.05, Table 2).
Given a potential target population of 28% patients coexpressing EGFR and mTOR pathways, we then evaluated the efficacy of RAD001 and erlotinib in SCLC cell lines (Figure 2A and B). Small cell lung cancer cells were treated with increasing doses of RAD001 (5, 10, 20 and 50 n) and erlotinib (5 and 10 μ) for 72 h.
RAD001 at doses of 5–50 n had no significant anti-tumour effect. However, 5 μ of erlotinib achieved a mild reduction of viable GLC-4 (16%) and VL-68 cells (26%) (see Figure 2A and B, P<0.001 compared with control) and this effect could not be increased using 10 μ of erlotinib. We did not use higher doses of erlotinib, as 5 μ erlotinib correspond to plasma concentrations in humans that can be achieved after oral dosing with 150 mg erlotinib per day (Hidalgo et al, 2001).
Combination treatment of VL-68 and GLC-4 cells (Figure 2A and B) revealed a strong, significant reduction of cell viability by up to 86% (s.d.±0.74%) and 72% (s.d.±2%), respectively, compared with the untreated control and the respective erlotinib or RAD001 monotherapy (all P<0.0001).
For further mechanistic insights, we analysed respective drug effects on cell DNA synthesis (3H-thymidine incorporation assay), cell cycle phases (PI staining), autophagy (acidic vesicular organelles) and apoptosis (DAPI staining and sub-G1 peak in cell cycle analysis). Treatment of VL-68 cells with 5 μ erlotinib for 24 h revealed a strong reduction of DNA synthesis by 74% compared with control (Figure 2C). Addition of RAD001 at all doses further decreased DNA synthesis of erlotinib to 14% of untreated control (P<0.003, compared with erlotinib or RAD001 monotherapy, respectively), thus showing a cooperative inhibitory effect of this drug combination on SCLC cell proliferation. Similar results were observed for the GLC-4 cell line (data not shown) and confirmed by cell cycle analysis. Cell cycle analysis showed a significant G0/G1 arrest with a corresponding significant reduction of S phase of tumour cells upon combination treatment compared with respective controls (see Figure 2D). Although apoptosis was no major contributor to the observed anti-tumour effects (unremarkable DAPI staining, no evidence for a sub-G1 peak in FACS analysis, data not shown), there was a significant effect of combinatorial therapy on autophagy. Treatment of VL-68 and GLC-4 cell lines with erlotinib and RAD001 led to a 22- and 47-fold induction of autophagy compared with control whereas respective monotherapies revealed only a little effect (Figure 2E).
Given the strong synergistic antitumour effect of erlotinib and RAD001 combination therapy compared with the respective monotherapy, we evaluated the mechanism of action of this combination by monitoring therapy-associated changes in both pathways (Figure 3A–C); both cell lines showed a weak EGFR expression on the protein level (Figure 3A). No mutations were found in EGFR gene exon 18–21. We next tested whether the EGFR was functional in both cell lines. Thus, SCLC cells were serum starved for 24 h, followed by specific EGFR stimulation using 100 ng ml–1 EGF in the presence or absence of erlotinib (Figure 3B). Stimulation of SCLC cells caused a significant induction of p-ERK in both cell lines. Erlotinib blocked EGF-derived p-ERK induction in the GLC-4 cell line and reduced p-ERK induction to baseline levels in the VL-68 cell line (Figure 3B). The same was true for p-AKT in the GLC-4 cell line, whereas p-AKT was not inducible in the VL-68 cell line, a cell line lacking basal p-AKT expression. These data confirmed that the EGFR was functional in both cell lines and activated downstream targets upon activation with its ligand EGF.
Finally, we evaluated the effects of both drugs alone and upon combination on both cell lines: erlotinib monotherapy of GLC-4 cells with 5 μ resulted in a clear downregulation of p-AKT, and significantly activated the mTOR pathway in terms of p-mTOR upregulation (Figure 3C), whereas erlotinib monotherapy of the p-AKT-negative VL-68 cell line with 5 μ caused a significant downregulation of p-ERK levels, and – similarly to the GCL-4 cell line – significantly activated the mTOR pathway in terms of p-mTOR upregulation (Figure 3C). RAD001 treatment of GLC-4 and VL-68 cells with 5 n resulted in the downregulation of p-mTOR and p-p70s6K. In addition, RAD001 influenced the EGFR pathway: there was a slight downregulation of p-ERK and p-AKT in the VL-68 and GLC-4 cell line, respectively. The combination of 5 μ erlotinib and 5 n RAD001 in GCl-4 cells caused a synergistic downregulation of p-AKT compared with erlotinib and RAD001 monotherapy. In the VL-68 cell line, the combination therapy synergised in terms of p-ERK downregulation compared with erlotinib monotherapy. In both cell lines, the mTOR pathway activation caused by erlotinib monotherapy was inhibited upon combination with RAD001.
Preclinical studies suggested synergistic effects upon combined EGFR and mTOR pathway inhibition in non-SCLC and breast (Buck et al, 2006), squamous cell carcinoma (Jimeno et al, 2007), glioblastoma (Wang et al, 2006), colon (Bianco et al, 2008), pancreatic cancer (Azzariti et al, 2008) and biliary tract cancer (Herberger et al, 2009). This is the first study testing the combination of EGFR targeting therapy with mTOR inhibitors for SCLC treatment.
First, we assessed single EGFR and mTOR pathway expression in 107 SCLC tissues. Surprisingly, EGFR receptor was expressed in 37% (see Table 2), which is more frequently than reported previously (Kaseda et al, 1989). In contrast, we found lower p-AKT and p-ERK expression when compared with other investigators (Blackhall et al, 2003). Moreover, we showed that expression of EGFR significantly correlated with its downstream target p-ERK. These results confirm in vivo the signalling information reported in various in vitro studies. Interestingly, patients receiving neoadjuvant chemotherapy with cisplatin and etoposid showed significantly lower EGFR expression than patients receiving no chemotherapy. Whether this reflects a true loss of EGFR receptor or a selection of EGFR-negative tumour cells remains to be investigated. However, reduced EGFR expression after chemotherapy could be, at least in part, responsible for the recent failure of a phase II clinical trial (Moore et al, 2006), testing gefitinib in chemotherapy pretreated SCLC patients.
The mTOR pathway was active in a significant proportion of patients in terms of p-mTOR (55%) and p-p70s6K (84%) expression (see Table 2). Similar to the association of EGFR and p-ERK, p-mTOR also showed its well-demonstrated association with p-p70s6K in vivo. Interestingly, mTOR pathway activation was stronger in earlier stages of disease. This finding could be important for future trial designs testing mTOR inhibitors in SCLC: a recently reported phase II clinical trial with the mTOR inhibitor everolimus (Owonikoko et al, 2008) in SCLC patients – including predominantly patients at an advanced stage of disease – failed to show significant clinical activity. In summary, EGFR and mTOR pathways were active in a significant proportion of patients with SCLC. Furthermore, 28% of SCLC patients showed coexpression of both pathways and may therefore represent the potential target population for combined anti-EGFR and mTOR targeting therapy.
Thus, we evaluated the efficacy of single- and dual-pathway inhibition in SCLC cell lines and investigated the mechanism of action of this combination at the molecular level. We found a synergistic antitumour effect upon combination of both drugs. The underlying mechanisms of the observed effect are complex and involve: (1) significant reduction of DNA synthesis (see Figure 2C), (2) a G0/G1 arrest with consecutive reduction of S phase (see Figure 2D), and (3) induction of autophagy (see Figure 2E), a mechanism that has been recently reported for mTOR inhibitors (Kim et al, 2006; Iwamaru et al, 2007; Crazzolara et al, 2009). In combination, these effects significantly contributed to the observed antitumour effect, whereas apoptosis did not seem to play a major role (unremarkable DAPI staining, no evidence for a sub-G1 peak in FACS analysis).
It is noteworthy that there was only a mild effect of erlotinib at a physiological dose in both cell lines (see Figure 2A and B) despite strong downregulation of p-AKT in GLC-4 cells and p-ERK in VL-68 cells (see Figure 3C). This might be explained by the absence of an activating EGFR mutation, which is a striking predictor for sensitivity of tumour cells to EGFR targeting therapy (Lynch et al, 2004; Ono and Kuwano, 2006). Compatibly, the only reported case showing clinical response was achieved in a patient carrying one of these activating mutations (Okamoto et al, 2006). Furthermore, the induction of mTOR signalling by erlotinib observed in this study may have contributed to the blunting of antitumour activity.
Similar to erlotinib, the efficacy of RAD001 monotherapy was not dose dependent and was lacking in both cell lines, despite target regulation in terms of p-mTOR and p-p70s6K downregulation. In contrast to previous reports (Buck et al, 2006; O'Reilly et al, 2006; Sieghart et al, 2007), there was no increase in AKT phosphorylation, which could have caused RAD001 resistance, leaving the mechanism of resistance unclear. Taken together, single EGFR or mTOR pathway inhibition seems ineffective for SCLC treatment in vitro, which may explain recent failures of mTOR and EGFR monotherapy in clinical trials of SCLC (Moore et al, 2006; Owonikoko et al, 2008).
Crucially, dual inhibition of EGFR and mTOR pathways by erlotinib and RAD001 combination therapy showed a synergistic and highly significant antitumour effect that could be explained on the molecular level by synergistic regulation of both pathways (see Figure 3C).
In summary, we found that the EGFR and mTOR pathways are active and coexpressed in a significant proportion of SCLC patients. A combination of erlotinib and RAD001 showed a synergistic antitumour effect, which was reflected on the molecular level, whereas respective monotherapies failed to prove significant antitumour efficacy. Therefore, this study provides a preclinical rationale to test dual inhibition of EGFR and mTOR pathways in SCLC in a prospective clinical trial.
This study was supported by a research grant from Roche Austria.
|Azzariti A,Porcelli L,Gatti G,Nicolin A,Paradiso A. Year: 2008Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cellsBiochem Pharmacol751035104418191814|
|Belyanskaya LL,Hopkins-Donaldson S,Kurtz S,Simões-Wuest AP,Yousefi S,Simon HU,Stahel R,Zangemeister-Wittke U. Year: 2005Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulationInt J Cancer11775576315981204|
|Berger W,Spiegl-Kreinecker S,Buchroithner J,Elbling L,Pirker C,Fischer J,Micksche M. Year: 2001Overexpression of the human major vault protein in astrocytic brain tumour cellsInt J Cancer9437738211745417|
|Bianco R,Garofalo S,Rosa R,Damiano V,Gelardi T,Daniele G,Marciano R,Ciardiello F,Tortora G. Year: 2008Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugsBr J Cancer9892393018319715|
|Bjornsti MA,Houghton PJ. Year: 2004The TOR pathway: a target for cancer therapyNat Rev Cancer433534815122205|
|Blackhall FH,Pintilie M,Michael M,Leighl N,Feld R,Tsao MS,Shepherd FA. Year: 2003Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancerClin Cancer Res92241224712796392|
|Buck E,Eyzaguirre A,Brown E,Petti F,McCormack S,Haley JD,Iwata KK,Gibson NW,Griffin G. Year: 2006Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumorsMol Cancer Ther52676268417121914|
|Ciardiello F,Tortora G. Year: 2008EGFR antagonists in cancer treatmentN Engl J Med3581160117418337605|
|Crazzolara R,Bradstock KF,Bendall LJ. Year: 2009RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemiaAutophagy572772819363300|
|Damstrup L,Rude Voldborg B,Spang-Thomsen M,Bruenner N,Skovgaard Poulsen H. Year: 1998In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptorBr J Cancer786316409744504|
|Dornetshuber R,Heffeter P,Kamyar MR,Peterbauer T,Berger W,Lemmens-Gruber R. Year: 2007Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activites against human cancer cellsChem Res Toxicol2046547317326668|
|Fischer B,Marinov M,Arcaro A. Year: 2007Targeting receptor tyrosine kinase signalling in small cell lung cancer (SLCL): what have we learned so farCancer Treat Rev3339140617368733|
|Herberger B,Berger W,Puhalla H,Schmid K,Novak S,Brandstetter A,Pirker C,Gruenberger T,Filipits M. Year: 2009Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cellsMol Cancer Ther81547155619509244|
|Hidalgo M,Siu LL,Nemunaitis J,Rizzo J,Hammond LA,Takimoto C,Eckhardt SG,Tolcher A,Britten CD,Denis L,Ferrante K,vonHoff DD,Silberman S,Rowinsky EK. Year: 2001Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesJ Clin Oncol193267327911432895|
|Hudes G,Carducci M,Tomczak P,Dutcher J,Figlin R,Kapoor A,Staroslawska E,Sosman J,McDermott D,Bodrogi I,Kovacevic Z,Lesovoy V,Schmidt-Wolf IG,Barbarash O,Gokmen E,O′Toole T,Lustgarten S,Moore L,Motzer RJ,Global ARCC TrialYear: 2007Temsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med3562271228117538086|
|Iwamaru A,Kondo Y,Iwado E,Aoki H,Fujiwara K,Yokoyama T,Mills GB,Kondo S. Year: 2007Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cellsOncogene261840185117001313|
|Jimeno A,Kulesza P,Wheelhouse J,Chan A,Zhang X,Kincaid E,Chen R,Clark DP,Forastiere A,Hidalgo M. Year: 2007Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacyBr J Cancer9695295917342092|
|Kaseda S,Ueda M,Ozawa S,Ishihara T,Abe O,Shimizu N. Year: 1989Expression of epidermal growth factor receptors in four histologic cell types of lung cancerJ Surg Oncol4216202549305|
|Kim KW,Mutter RW,Cao C,Albert JM,Freeman M,Hallahan DE,Lu B. Year: 2006Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signalingJ Biol Chem281368833689017005556|
|Lynch TJ,Bell DW,Sordella R,Gurubhagavatula S,Okimoto RA,Brannigan BW,Harris PL,Haserlat SM,Supko JG,Haluska FG,Louis DN,Christiani DC,Settleman J,Haber DA. Year: 2004Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med3502129213915118073|
|Moore AM,Einhorn LH,Estes D,Govindan R,Axelson J,Vinson J,Breen TE,Yu M,Hanna NH. Year: 2006Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trialLung Cancer52939716488055|
|Motzer RJ,Escudier B,Oudard S,Hutson TE,Porta C,Bracarda S,Gruenwald V,Thompson JA,Figlin RA,Hollaender N,Urbanowitz G,Berg WJ,Kay A,Lebwohl D,Ravaud A,RECORD-1 Study Group.Year: 2008Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet37244945618653228|
|Nakamura Y,Oka M,Soda H,Shiozawa K,Yoshikawa M,Itoh A,Ikegami Y,Tsurutani J,Nakatomi K,Kitazaki T,Doi S,Yoshida H,Kohno S. Year: 2005Gefitinib (‘Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistanceCancer Res651541154615735043|
|Okamoto I,Araki J,Suto R,Shimada M,Nakagawa K,Fukuoka M. Year: 2006EGFR mutation in gefitinib-responsive small-cell lung cancerAnn Oncol171028102916357019|
|Ono M,Kuwano M. Year: 2006Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugsClin Cancer Res127242725117189395|
|O'Reilly KE,Rojo F,She QB,Solit D,Mills GB,Smith D,Lane H,Hofmann F,Hicklin DJ,Ludwig DL,Baselga J,Rosen N. Year: 2006mTOR inhibition induces upstream receptor kinase signaling and activates AktCancer Res661500150816452206|
|Owonikoko TK,Stoller RG,Petro D,Flaugh R,Hershberger PA,Belani CP,Argiris AE. Year: 2008Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancerJ Clin Oncol Suppl2619017|
|Pandya KJ,Levy DE,Hidalgo M,Cohen RB,Lee MW,Schiller JH,Johnson DH. Year: 2005A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapyJ Clin Oncol Suppl237005|
|Puglisi M,Dolly S,Faria A,Myerson JS,Popat S,O'Brien HE. Year: 2010Treatment options for small cell lung cancer – do we have more choiceBritish J Cancer102629638|
|Sieghart W,Fuereder T,Schmid K,Cejka D,Werzowa J,Wrba F,Wang X,Gruber D,Rasoul-Rockenschaub S,Peck-Radosavljevic M,Wacheck V. Year: 2007Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantationTransplantation8342543217318075|
|Tanno S,Ohsaki Y,Nakanishi K,Toyoshima E,Kikuchi K. Year: 2004Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib (‘Iressa', ZD1839)Oncol Rep121053105715492792|
|Wang MY,Lu KV,Zhu S,Dia EQ,Vivanco I,Shackleford GM,Cavenee WK,Mellinghoff IK,Cloughesy TF,Sawyers CL,Mischel PS. Year: 2006Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibition in PTEN-deficient and PTEN-intact glioblastoma cellsCancer Res667864786916912159|
|Wu C,Wangpaichitr M,Feun L,Kuo MT,Robles C,Lampidis T,Savaraj N. Year: 2005Overcoming cisplatin resistance by mTOR inhibitor in lung cancerMol Cancer42516033649|
|Zijlstra JG,de Vries EG,Mulder NH. Year: 1987Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell lineCancer Res47178017843028613|
Keywords: small cell lung cancer, EGFR, mTOR, erlotinib, RAD001, targeted therapy.
Previous Document: Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening.
Next Document: 7-O-descarbamoyl-7-hydroxygeldanamycin, a minor component from the gdmN disruption mutant of Strepto...